Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of “switch” maintenance, the use of medicines not included in initial induction therapy, in this setting. NINLARO is currently not approved for this specific use.
“We are very encouraged by the results of the TOURMALINE-MM4 trial and continue our forward momentum in developing maintenance options for multiple myeloma patients. Importantly, this is the third positive Phase 3 readout from the TOURMALINE clinical trial program,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “We remain committed to bringing this convenient and well-tolerated treatment option to patients.”
The safety profile of NINLARO in the maintenance setting was consistent with previously reported results of single-agent NINLARO use, and there were no new safety signals identified in TOURMALINE-MM4.
Full data results will be submitted for presentation at an upcoming medical meeting.
About the TOURMALINE-MM4 Trial
TOURMALINE-MM4 is a randomized, placebo-controlled, double-blind Phase 3 study of 706 patients, designed to determine the effect of single-agent oral NINLAROTM (ixazomib) maintenance therapy on progression-free survival (PFS), compared to placebo, in adult patients newly diagnosed with multiple myeloma not treated with stem cell transplantation, who have completed 6-12 months of initial therapy and achieved a partial response or better. For additional information, please visit https://clinicaltrials.gov/ct2/show/NCT02312258.
About Multiple Myeloma
Multiple myeloma is a life-threatening rare blood cancer that arises from the plasma cells, a type of white blood cell that is made in the bone marrow. These plasma cells become abnormal, multiply and release a type of antibody known as a paraprotein, which causes symptoms of the disease, including bone pain, frequent or recurring infections and fatigue, a symptom of anemia. These malignant plasma cells have the potential to affect many bones in the body and can cause a number of serious health problems affecting the bones, immune system, kidneys and red blood cell count. The typical multiple myeloma disease course includes periods of symptomatic myeloma followed by periods of remission. Nearly 230,000 people around the world live with multiple myeloma, with approximately 114,000 new cases diagnosed globally each year.
About NINLAROTM (ixazomib) capsules
NINLARO™ (ixazomib) is an oral proteasome inhibitor which is being studied across the continuum of multiple myeloma treatment settings. NINLARO was first approved by the U.S. Food and Drug Administration (FDA) in November 2015 and is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is currently approved in more than 60 countries, including the United States, Japan and in the European Union, with more than 10 regulatory filings currently under review. It was the first oral proteasome inhibitor to enter Phase 3 clinical trials and to receive approval.
The comprehensive ixazomib clinical development program, TOURMALINE, includes several ongoing pivotal trials, which together are investigating major multiple myeloma patient populations:
- TOURMALINE-MM1, investigating ixazomib vs. placebo in combination with lenalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
- TOURMALINE-MM2, investigating ixazomib vs. placebo in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
- TOURMALINE-MM3, investigating ixazomib vs. placebo as maintenance therapy in patients with newly diagnosed multiple myeloma following induction therapy and autologous stem cell transplant (ASCT)
- TOURMALINE-MM4, investigating ixazomib vs. placebo as maintenance therapy in patients with newly diagnosed multiple myeloma who have not undergone ASCT
In addition to the TOURMALINE program, ixazomib is being evaluated in multiple therapeutic combinations for various patient populations in investigator initiated studies globally.
NINLAROTM (ixazomib) capsules: Global Important Safety Information
SPECIAL WARNINGS AND PRECAUTIONS
Thrombocytopenia has been reported with NINLARO (28% vs. 14% in the NINLARO and placebo regimens, respectively) with platelet nadirs typically occurring between Days 14-21 of each 28-day cycle and recovery to baseline by the start of the next cycle. It did not result in an increase in hemorrhagic events or platelet transfusions. Monitor platelet counts at least monthly during treatment with NINLARO and consider more frequent monitoring during the first three cycles. Manage with dose modifications and platelet transfusions as per standard medical guidelines.
Gastrointestinal toxicities have been reported in the NINLARO and placebo regimens respectively, such as diarrhea (42% vs. 36%), constipation (34% vs. 25%), nausea (26% vs. 21%), and vomiting (22% vs. 11%), occasionally requiring use of antiemetic and anti-diarrheal medications, and supportive care.
Peripheral neuropathy was reported with NINLARO (28% vs. 21% in the NINLARO and placebo regimens, respectively). The most commonly reported reaction was peripheral sensory neuropathy (19% and 14% in the NINLARO and placebo regimens, respectively). Peripheral motor neuropathy was not commonly reported in either regimen (< 1%). Monitor patients for symptoms of peripheral neuropathy and adjust dosing as needed.
Peripheral edema was reported with NINLARO (25% vs. 18% in the NINLARO and placebo regimens, respectively). Evaluate patients for underlying causes and provide supportive care, as necessary. Adjust the dose of dexamethasone per its prescribing information or the dose of NINLARO for severe symptoms.
Cutaneous reactions occurred in 19% of patients in the NINLARO regimen compared to 11% of patients in the placebo regimen. The most common type of rash reported in both regimens was maculo-papular and macular rash. Manage rash with supportive care, dose modification or discontinuation.
Hepatotoxicity, drug-induced liver injury, hepatocellular injury, hepatic steatosis, and hepatitis cholestatic have been uncommonly reported with NINLARO. Monitor hepatic enzymes regularly and adjust dose for Grade 3 or 4 symptoms.
Pregnancy- NINLARO can cause fetal harm. Advise male and female patients of reproductive potential to use contraceptive measures during treatment and for an additional 90 days after the final dose of NINLARO. Women of childbearing potential should avoid becoming pregnant while taking NINLARO due to potential hazard to the fetus. Women using hormonal contraceptives should use an additional barrier method of contraception.
Lactation- It is not known whether NINLARO or its metabolites are excreted in human milk. There could be potential adverse events in nursing infants and therefore breastfeeding should be discontinued.
SPECIAL PATIENT POPULATIONS
Hepatic Impairment: Reduce the NINLARO starting dose to 3 mg in patients with moderate or severe hepatic impairment.
Renal Impairment: Reduce the NINLARO starting dose to 3 mg in patients with severe renal impairment or end-stage renal disease (ESRD) requiring dialysis. NINLARO is not dialyzable and, therefore, can be administered without regard to the timing of dialysis.
Co-administration of strong CYP3A inducers with NINLARO is not recommended.
The most frequently reported adverse reactions (≥ 20%) in the NINLARO regimen, and greater than in the placebo regimen, were diarrhea (42% vs. 36%), constipation (34% vs. 25%), thrombocytopenia (28% vs. 14%), peripheral neuropathy (28% vs. 21%), nausea (26% vs. 21%), peripheral edema (25% vs. 18%), vomiting (22% vs. 11%), and back pain (21% vs. 16%). Serious adverse reactions reported in ≥ 2% of patients included thrombocytopenia (2%) and diarrhea (2%). For each adverse reaction, one or more of the three drugs was discontinued in ≤ 1% of patients in the NINLARO regimen.
For European Union Summary of Product Characteristics:
For US Prescribing Information: https://www.ninlarohcp.com/pdf/prescribing-information.pdf
For Canada Product Monograph: http://www.takedacanada.com/ninlaropm
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takeda’s estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s), any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key Information—D. Risk Factors” in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Key Leadership Appointments Support Syngenta’s Continued Investment and Commitment to European Seeds Business27.5.2020 10:00:00 CEST | Press release
Syngenta has announced three strategic leadership appointments supporting the continued growth and investment in its European and global Seeds business. Gaël Hili, currently Crop Protection Head East Europe, is appointed Regional Director for Europe, Africa and Middle East (EAME) Seeds, taking over leadership of the region from Justin Wolfe, who has served as Regional Director EAME Seeds since 2018 and is appointed Regional Director for North America Seeds. “The important European seeds market is a must-win for Syngenta. Under Justin’s leadership, we have created a specialized Seeds organization, enabling us to bring growers the deep agronomic advice they need,” said Jeff Rowe, President Syngenta Seeds. “We have significantly increased the size of our grower-facing commercial and technical teams, and have expanded our corn and sunflower portfolio.” Gaël Hili joined Syngenta in 2017 as Head Europe East, and under his leadership, the team grew market share across both the Seeds and Crop
Jefferies to Hold Global Coronavirus Relief Charity Day Today Dedicated to the Memory of Peg Broadbent27.5.2020 09:00:00 CEST | Press release
Jefferies announced that it is holding its Global Coronavirus Relief Charity Day today. The firm and its staff will contribute to global charities and relief efforts to assist those suffering from the devastation caused by the Coronavirus global pandemic and will offer investors around the world the opportunity to join these efforts by trading with Jefferies. Jefferies will dedicate this entire effort to their late CFO Peg Broadbent, who was a victim of this terrible disease. As previously announced, Jefferies will donate net commissions from trading today, Wednesday, May 27th, for all global trading in equities, fixed income and foreign exchange by the firm’s clients. In addition, Jefferies as a firm will donate $1 million directly, and all 3,822 employees worldwide will be given the opportunity to donate to these efforts. These contributions will be allocated to a series of charities on the front lines in fighting this ongoing global pandemic and providing urgently needed relief for
MILSPED GROUP Relies on the Shippeo Platform to Meet the Growing Real-time Transportation Visibility Needs of Its Customers27.5.2020 09:00:00 CEST | Press release
Milšped, a leading international transport and logistics group, has chosen Shippeo, the European leader in supply chain visibility, to track in real-time all of its FTL and LTL operations operated by both its own fleet and its subcontracting partners. The large expertise of Shippeo in managing complex LTL operations in Europe has been a key decision criterion for Milšped to adopt the visibility platform. Milšped Group provides numerous integrated services, including customs clearance and brokerage, organization of international and domestic transportation and distribution, as well as warehousing solutions. The Serbian group has a strong presence throughout the Balkans as well as in Germany, Russia, China and the USA. Deputy Director for international transport Marko Cavoski is thrilled to be working with Shippeo. It is part of their strategy to invest in innovative solutions to lead in customer satisfaction. “As a 3PL, we work with more than 580 subcontractors on well over 200,000 orde
REPLY: Gartner Names Reply a Visionary in the 2020 Magic Quadrant for Warehouse Management Systems27.5.2020 09:00:00 CEST | Press release
Gartner, a leading IT research and strategic consulting firm, has positioned Reply, specialised in the design and implementation of solutions based on new communication channels and digital media, among the Visionaries in their “Magic Quadrant for Warehouse Management Systems” 2020. The report evaluates 15 vendors, focusing on warehouse management systems, software applications that support companies in optimising the execution of warehouse or distribution centre processes. Reply has been named in the Visionaries quadrant thanks to its proprietary suites: https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.reply.com%2Flea-reply%2Fen%2F&esheet=52225582&newsitemid=20200527005029&lan=en-US&anchor=LEA+ReplyTM&index=1&md5=25068938af51b5eec2b816283a93627b LEA ReplyTM and https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.reply.com%2Fclick-reply%2Fen%2F&esheet=52225582&newsitemid=20200527005029&lan=en-US&anchor=Click+ReplyTM&index=2&md5=074a995de316106a29d
SmartStream Extends Public API to Promote Access to Collateral Management Technologies27.5.2020 09:00:00 CEST | Press release
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today extended its Public API (Application Programming Interface) for collateral management, to enable its clients with faster access technology to better service their individual business needs. The approach has been taken to deliver a Public API which allows clients to have direct programmatic access to SmartStream’s TLM Collateral Management solution. This helps to lower the total cost of ownership, provides backward compatibility and future-proofs the solution for new operational requirements, with minimal disruption to the clients’ business. TLM Collateral Management has extended the rich functionality of its Public API to include collateral movements notifications. The technology has been designed to provide collateral movement and settlement views for the early indication of collateral fails. Other functionality includes, but are not limited to, workflow automation and agreement u
Devexperts Launches DXtrade as a SaaS Trading Platform for FX/CFD Brokers27.5.2020 08:00:00 CEST | Press release
Devexperts, a software provider for the financial industry, launched DXtrade, a new SaaS (Software-as-a-Service) trading platform for the retail FX and CFD industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005154/en/ DXtrade, a SaaS trading platform for CFD Brokers (Graphic: Business Wire) DXtrade is an off the shelf trading solution for CFD brokers with robust risk management and back office applications. Its flexibility in settings allows brokers to achieve their ideal setup in both their trading platform front ends and brokerage operations. DXtrade has been designed as a trading platform that allows brokers to differentiate themselves from the wider market as all layouts and setups of the platform are determined by the broker. This high degree of automation and customisation also extends to the back-end configurations where brokers can set up limits, rebates, margins, spreads, and client execution on instrume